Clinical Trial Update: Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas [Phase 1]

View source ↗

Summary

A Phase 1 trial of Ulixertinib (BVD-523) in combination with hydroxychloroquine for patients with advanced MAPK-mutated gastrointestinal adenocarcinomas has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Adenocarcinoma
• Gastrointestinal Neoplasms

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)
• Ulixertinib (ulixertinib)

Snippet

Sponsor: University of Utah | Conditions: Gastrointestinal Neoplasms | Phase 1 | Status: COMPLETED